Illouz F, Dubois-Ginouves S, Laboureau S, Rohmer V, Rodien P
Service d'Endocrinologie, CHU Hôtel Dieu, 4 rue Larrey, 49033 Angers cedex 01.
Ann Endocrinol (Paris). 2006 Sep;67(4):353-6. doi: 10.1016/s0003-4266(06)72611-7.
Cabergoline is a dopaminergic agonist with demonstrated efficiency of for the treatment of prolactin-secreting pituitary tumors. It has also been reported effective for patients with hypercortisolism uncontrolled by conventional therapies. We describe the use of cabergoline in three patients with Cushing's disease, one of them presenting a silent ACTH-secreting pituitary tumor. Those patients underwent surgery and only one has been treated with radiation therapy. However persisting hypercortisolism motivated the use of cabergoline. We describe a decrease or a normalization in hypercortisolism; for one of the subjects, tumor growth seemed to be stopped. While cabergoline can induce a suppression of cortisol secretion or a corticotroph tumor shrinkage, the sites of action remain unclear.
卡麦角林是一种多巴胺能激动剂,已证明其对治疗分泌催乳素的垂体肿瘤有效。也有报道称,它对常规治疗无法控制的皮质醇增多症患者有效。我们描述了卡麦角林在3例库欣病患者中的应用,其中1例为无功能促肾上腺皮质激素分泌型垂体肿瘤。这些患者接受了手术,只有1例接受了放射治疗。然而,持续的皮质醇增多症促使使用卡麦角林。我们描述了皮质醇增多症的减轻或恢复正常;对于其中1例患者,肿瘤生长似乎停止了。虽然卡麦角林可抑制皮质醇分泌或使促肾上腺皮质激素肿瘤缩小,但其作用部位仍不清楚。